There are currently three biologics registered in the EU and US as an add-on treatment of severe CRSwNP: omalizumab (anti-IgE) [160], mepolizumab (anti-IL5) [161], and dupilumab (anti-IL4/13) [162]. This evidence concerns the gene IL5 and chronic rhinosinusitis with nasal polyps.